

References

L-123

1. Heitzer E, Ulz P, Geigl JB. Circulating tumor DNA as a liquid biopsy for cancer. *Clinical Chemistry*. 2015;61(1): 112-123.
2. National Cancer Institute. NCI dictionary of cancer terms: liquid biopsy.
3. Schwaederle M, Husain H, Fantal PT, et al. Detection rate of actionable mutations in diverse cancers using a biopsy-free (blood) circulating tumor cell DNA assay. *Oncotarget*. 2016.
4. National Comprehensive Cancer Network 2017 Clinical Practice Guidelines in Oncology: Non-Small Cell Lung Cancer. V.6.2017.
5. Lanman RB, Mortimer SA, Zill OA, et al. Analytical and clinical validation of a digital sequencing panel for quantitative, highly accurate evaluation of cell-free circulating tumor DNA. *Plos One*. 2015;10(10):1-27.
6. Lebofsky R, Decraene C, Bernard V, et al. Circulating tumor DNA as a non-invasive substitute to metastasis biopsy for tumor genotyping and personalized medicine in a prospective trial across all tumor types. *Molecular Oncology*. 2015:1-8.
7. Sundaresan TK, Sequist LV, Heymach JV, et al. Detection of T790M, the acquired resistance EGFR mutation, by tumor biopsy versus noninvasive blood-based analyses. *American Association for Cancer Research*. 2015:1103-1110.
8. Bettgowda C, Sausen M, Leary RJ, et al. Detection of circulating tumor DNA in early- and late-stage human malignancies. *Sci Transl Med*. 2014;6(224):1-25.
9. Dawson SJ, Tsui DWY, Murtaza M, et al. Analysis of circulating tumor DNA to monitor metastatic breast cancer. *NEJM*. 2013;368(13):1199-1209.
10. Clinical Trials.gov. Tracking non-small cell lung cancer evolution through therapy (Rx) (TRACERx).